Akcea Therapeutics has been acquired by Ionis Pharmaceuticals. For continued news and information about Akcea Therapeutics, please visit ionispharma.com. You are being redirected, please wait. If you have not been redirected in 30 seconds, please click the button below.
Akcea Therapeutics a été racheté par Ionis Pharmaceuticals. Pour des nouvelles et des informations continues sur Akcea Therapeutics, veuillez visiter ionispharma.com. Vous êtes redirigé, veuillez patienter. Si vous n'avez pas été redirigé depuis 30 secondes, veuillez cliquer sur le bouton ci-dessous.
hATTR Compass Genetic Testing and Counseling Program
Akcea Therapeutics and Ambry Genetics are partnering to offer anonymous, no-cost genetic testing and confidential genetic counseling to patients suspected of having or clinically diagnosed with hATTR amyloidosis through the hATTR Compass program.
hATTR Compass is Designed to:
Help accelerate or confirm the diagnosis of hATTR amyloidosis
Provide support and resources to patients, caregivers and healthcare professionals throughout the genetic testing process
Empower patients and their healthcare professionals to make the most informed decisions about their health care
The hATTR Compass Program is available for patients in the U.S. and Canada who are 18 years and older and have a family history of hATTR amyloidosis. If there is no family history, the patient must have at least two clinical symptoms or manifestations related to hATTR amyloidosis.
Help Your Patients Stay Connected with Backpack Health
Backpack Health is a mobile and web-based app that helps patients keep track of their symptoms, procedures, diagnostic tests and ongoing treatment for hATTR amyloidosis. The tool also makes it easy for individuals and families navigating the hATTR amyloidosis journey to share important medical information with healthcare professionals. Access to the app is complimentary for patients with hATTR amyloidosis at join.backpackhealth.com/hATTRCompass.